A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs Lemborexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Eisai Inc
- 11 Jun 2019 According to an Eisai Inc media release, results from the study were presented at the 33rd annual meeting of the Associated Professional Sleep Societies (SLEEP 2019).
- 11 Jun 2019 Results presented in an Eisai Inc media release.
- 28 May 2019 According to an Eisai Co Ltd media release, the company today announced the results of this study will be presented at the 33rd annual meeting of the Associated Professional Sleep Societies (SLEEP 2019) June 10 in San Antonio.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History